A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
Public ClinicalTrials.gov record NCT00740051. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, db, Placebo-controlled, Parallel Group Efficacy and Safety Study of BI 1356 (5mg), Administered Orally Once Daily for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients With Insufficient Glycaemic Control for Whom Metformin Therapy is Inappropriate (Intolerability or Contraindication)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication). The second part of the study looks at the safety of BI 1356 in this patient population with longer term treatment in comparison to a sulfonylurea drug (glimepiride)
Study identification
- NCT ID
- NCT00740051
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 227 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2008 (Type not available)
- Primary completion
- Aug 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 27, 2014
Started 2008
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1218.50.10009 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1218.50.10011 Boehringer Ingelheim Investigational Site | Peoria | Arizona | — | — |
| 1218.50.10013 Boehringer Ingelheim Investigational Site | Greenbrae | California | — | — |
| 1218.50.10016 Boehringer Ingelheim Investigational Site | Harbor City | California | — | — |
| 1218.50.10017 Boehringer Ingelheim Investigational Site | Huntington Park | California | — | — |
| 1218.50.10006 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1218.50.10007 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1218.50.10004 Boehringer Ingelheim Investigational Site | Statesville | North Carolina | — | — |
| 1218.50.10002 Boehringer Ingelheim Investigational Site | Eugene | Oregon | — | — |
| 1218.50.10015 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1218.50.10005 Boehringer Ingelheim Investigational Site | Kingsport | Tennessee | — | — |
| 1218.50.10012 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1218.50.10022 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1218.50.10010 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1218.50.10018 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00740051, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2014 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00740051 live on ClinicalTrials.gov.